Nektar Therapeutics (NKTR)
NASDAQ: NKTR · Real-Time Price · USD
8.51
-0.10 (-1.16%)
At close: Jun 20, 2025, 4:00 PM
9.65
+1.14 (13.40%)
Pre-market: Jun 23, 2025, 5:24 AM EDT
Nektar Therapeutics Revenue
Nektar Therapeutics had revenue of $10.46M in the quarter ending March 31, 2025, a decrease of -51.66%. This brings the company's revenue in the last twelve months to $87.25M, down -3.24% year-over-year. In the year 2024, Nektar Therapeutics had annual revenue of $98.43M with 9.22% growth.
Revenue (ttm)
$87.25M
Revenue Growth
-3.24%
P/S Ratio
1.36
Revenue / Employee
$1,430,295
Employees
61
Market Cap
105.58M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 98.43M | 8.31M | 9.22% |
Dec 31, 2023 | 90.12M | -1.93M | -2.10% |
Dec 31, 2022 | 92.06M | -9.85M | -9.67% |
Dec 31, 2021 | 101.91M | -51.01M | -33.36% |
Dec 31, 2020 | 152.92M | 38.30M | 33.41% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
NKTR News
- 11 days ago - Nektar Therapeutics: 2 Data Readouts For REZPEG 2025 Could Establish Further POC - Seeking Alpha
- 12 days ago - AMBROSIA & NEKTAR Introduces Premium High-End Organic Food from Greece with a Commitment to Purity and Provenance - GlobeNewsWire
- 5 weeks ago - Nektar Therapeutics to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference - PRNewsWire
- 6 weeks ago - Nektar Therapeutics (NKTR) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 6 weeks ago - Nektar Therapeutics Reports First Quarter 2025 Financial Results - PRNewsWire
- 7 weeks ago - Nektar to Announce Financial Results for the First Quarter on Thursday, May 8, 2025, After Close of U.S.-Based Financial Markets - PRNewsWire
- 3 months ago - Nektar Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference - PRNewsWire
- 3 months ago - Nektar Therapeutics (NKTR) Q4 2024 Earnings Call Transcript - Seeking Alpha